<DOC>
	<DOCNO>NCT01196728</DOCNO>
	<brief_summary>The primary objective study assess safety tolerability Glucagon-like peptide-1 ( GLP-1 ) peptide analogue CM3.1-AC100 single subcutaneous ( sc ) dose patient T2DM .</brief_summary>
	<brief_title>Single-centre , Randomised , Double-blind , Placebo-controlled , Four-way Crossover Clinical Study Investigate Safety Tolerability Pharmacokinetics Single Doses CM3.1-AC100 Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Provision sign date informed consent prior study specific procedures 2 . Type 2 diabetes mellitus patient , diagnostically confirm since least 6 month 3 . Male female patient age 18 75 year screen , inclusive 4 . BMI &gt; 22 â‰¤40 kg/m2 screen 1 . Type 1 diabetes mellitus , diabetes result pancreatic injury , secondary form diabetes , eg Cushings 's syndrome acromegaly 2 . Fasting Cpeptide &lt; 500 pM screen 3 . Acute gastrointestinal symptom time screen and/or Day 1 4 . Any clinically relevant history presence cardiovascular , bronchopulmonary , gastrointestinal neurological disease inclusive history chronic pancreatitis acute pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>